Age-related macular degeneration (AMD) is the leading cause of visual loss in those over 65 years of age in the developed world. Advanced AMD consists of two forms, dry (geographic atrophy or GA) and wet (neovascular AMD): both can coexist. It is increasingly considered that dry AMD may be the default pathway of ageing. While there is currently no medical treatment for dry AMD, wet AMD can be treated using regular intravitreal injections of anti-vascular endothelial growth factor antibodies (anti-VEGFs) such as ranibizumab and aflibercept. Such treatment preserves visual acuity in most patients by preventing scarring.

Excess VEGF inhibition may contribute to GA. In the Comparison of AMD Treatment Trial (CATT) 1185 participants with wet AMD were treated with anti-VEGFs. For the 1011 with no GA at baseline, the cumulative incidence of GA was 17% at 2 years.[@b1] It's not clear if this was associated with the pathological progress of AMD, or was an effect of intravitreal anti-VEGFS or was part of normal ageing. Animal models indicate a physiological role for VEGF secreted by the retinal pigment epithelium in the maintenance of choriocapillaris health, crucial for outer retinal function.[@b2] However interesting the debate may be, the benefits of anti-VEGFs for most patients should be remembered. In the CATT and in the Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) trial,[@b3] both trials comparing anti-VEGF drugs and regimens for wet AMD, the overall mean visual acuity gain after two years of anti-VEGFs was an impressive three lines of vision on the visual acuity charts used.[@b1]^,^[@b3] The advent of anti-VEGFs in ophthalmology 10 years ago led to a paradigm shift in the treatment of many retinal diseases, transforming outcomes for patients. Patient centered treatment is an ideal approach, but the present challenge is to optimise regimens for wet AMD for the large number of patients requiring treatment.
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